Sanofi Gains Therapeutic Cancer Vaccine TroVax In Deal With Oxford BioMedica
This article was originally published in The Pink Sheet Daily
Executive Summary
Announcement of the $690 million deal comes one day ahead of an advisory committee meeting for Provenge, the first therapeutic cancer vaccine to reach FDA.
You may also be interested in...
Oxford BioMedica/Sanofi Make Headway With FDA On TroVax Cancer Vaccine
Drug makers reaffirm commitment to developing TroVax, a therapeutic vaccine for renal cancer and potentially colorectal cancer.
Oxford BioMedica/Sanofi Make Headway With FDA On TroVax Cancer Vaccine
Drug makers reaffirm commitment to developing TroVax, a therapeutic vaccine for renal cancer and potentially colorectal cancer.
Oxford BioMedica/Sanofi Make Headway With FDA On TroVax Cancer Vaccine
After facing a setback with the therapeutic cancer vaccine TroVax in July, partners Oxford BioMedica and Sanofi-Aventis are reaffirming their commitment to develop the vaccine for the treatment of renal cancer and potentially colorectal cancer following a meeting with FDA